top of page

FDA Grants Breakthrough Therapy Designation to Edaravone Dexborneol Combination Therapy for Acute Ischemic Stroke

전한울

2024년 9월 7일

Edaravone dexborneol is a multi-target medication with both antioxidant and anti-inflammatory characteristics.

Widget Didn’t Load

Check your internet and refresh this page.

If that doesn’t work, contact us.

bottom of page